Authors
Latest:
Dr. Puri on Clinically Relevant Biomarkers in SCLCSonam Puri, MD, discusses recent research on clinically relevant biomarkers in small cell lung cancer.
Latest:
Incorporating Treatment Advances Into mRCC ManagementExpectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.
Latest:
Dr. Atkins on Safety Considerations For Neoadjuvant Approaches in Gastric CancerKatelyn M. Atkins, MD, PhD, discusses safety considerations for neoadjuvant approaches in patients with gastric cancer.
Latest:
Finding the Optimal Therapeutic Sequence for Advanced Hepatocellular CarcinomaSeveral breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.
Latest:
Emerging Strategies in the Management of Relapsed/Refractory CLLConsiderations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.
Latest:
Dr. Heimbach on the Need for Multidisciplinary Care in HCCJulie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.
Latest:
Dr Sikov on the Use of CDK4/6 Inhibitors in the First-line Treatment of ER+/HER2- Breast CancerWilliam M. Sikov, MD, discusses the negative outcome seen with palbociclib in the phase 3 PALOMA-2 trial, and compares this to data on other CDK4/6 inhibitors in the first-line treatment of estrogen receptor–positive, HER2-negative breast cancers.
Latest:
Dr. Ozguroglu on the Individualization of Treatment in NSCLCMustafa Özguröğlu, MD, discusses the individualization of treatment in non-small cell lung cancer.
Latest:
Dr Arbour on the Safety and Efficacy of RMC-6236 in KRAS-Mutant NSCLCKathryn C. Arbour, MD, discusses preliminary safety and efficacy data with the RAS inhibitor RMC-6236 in patients with KRAS-mutated non–small cell lung cancer.
Latest:
Optimizing Treatment Selection for Patients with FLT3-ITD AMLDiscussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.
Latest:
Dr. Evangelist on the Goals of the MYLUNG Consortium in Lung CancerMakenzi Evangelist, MD, discusses the goals of the MYLUNG Consortium in lung cancer.
Latest:
The Future of Metastatic and Unresectable Melanoma TreatmentThe panel concludes their discussion with a call for continued research and collaboration, emphasizing the need for more understanding of targeted therapies, monitoring tools like ctDNA, and ongoing development in the field of BRAF mutant melanoma treatment.
Latest:
Future Directions for mCRC ManagementGerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.
Latest:
Dr Maksimovic on a Novel Preclinical Model of Bone Metastasis in ccRCCStefan Maksimovic, MD, discusses the preclinical investigation of innovative tissue engineering with optical windows, state-of-the-art fluorescence reporter technology, and intravital multiphoton microscopy in mouse models with clear cell renal cell carcinoma.
Latest:
Dr. Kurtzberg on Long-term OS for Remestemcel-L in Pediatric Steroid-Refractory aGVHDJoanne Kurtzberg, MD, discusses the long-term survival outcomes from an observational cohort study evaluating remestemcel-L in pediatric patients with steroid-refractory acute graft-vs-host disease.
Latest:
Dr. Cheng on Advances With Immunotherapy-Based Combinations in OncologyJonathan D. Cheng, MD, discusses advances with immunotherapy-based combinations in oncology.
Latest:
Dr Kraft on VEGF Inhibitor–Induced Hypertension in RCCShawna Kraft, PharmD, BCOP, discusses the incidence and mitigation of VEGF inhibitor–induced hypertension in patients with renal cell carcinoma (RCC).
Latest:
American Oncology Network Celebrates Momentous Five-Year Anniversary of Closing the Cancer Care GapAmerican Oncology Network, one of the fastest-growing community oncology networks in the United States, proudly celebrated its fifth anniversary, commemorating a half-decade of excellence in advancing community oncology and driving value-based care initiatives to close the cancer care gap.
Latest:
Leveraging Immunotherapy in GI Malignancies: Looking to the FutureIn this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
Latest:
Incorporating ctDNA Into Routine Practice: Clinical PearlsAdvice to GI oncologists in the community on using ctDNA testing to detect minimal residual disease and inform treatment decisions in colorectal cancer.
Latest:
The Importance of Lung Cancer Screening in Individuals Exposed to the World Trade Center DisasterInvestigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.
Latest:
Targeted Treatment of Rare Childhood LeukemiaUCSF researcher to lead multicenter precision medicine trial for juvenile myelomonocytic leukemia.
Latest:
Dr Shen on the Utility of ARX517 in mCRPCJohn Shen, MD, discusses the utility of ARX517 in patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Nieto on High-Dose Chemotherapy and ASCT in R/R Multiple MyelomaYago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.
Latest:
Dr. King on Delays in Access to Germline Testing in Pancreatic CancerDaniel King, MD, PhD, discusses socioeconomic disparities causing delays in germline genetic testing for patients with pancreatic cancer.
Latest:
Dr. Wang on Challenges With Checkpoint Inhibitors in CRCTimothy Cragin Wang, MD, discusses the lack of response to checkpoint inhibitors in colorectal cancer.
Latest:
Dr Murthy on the Use of CAR T-Cell Therapy in Elderly or Frail Patients With B-Cell LymphomasHemant S. Murthy, MD, discusses the evolving use of CAR T-cell therapy for elderly or frail patients with relapsed/refractory B-cell lymphomas.
Latest:
Women in Oncology: Prioritization and Passionate LegaciesSelina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.
Latest:
Dr Cun on Molecular Classification in Endometrioid Endometrial AdenocarcinomaHan T. Cun, MD, MS, discusses the findings from a retrospective comprehensive molecular classification of patients with grade 3 endometrioid endometrial adenocarcinoma.
%201%20(1)%20copy.jpg?fit=crop&auto=format)
